Phase II Maraviroc for GVHD Prevention
NCT01785810
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Hematologic Malignancy
Interventions
DRUG:
Maraviroc 300 mg
Sponsor
Abramson Cancer Center at Penn Medicine